Published in Br J Cancer on March 01, 1999
p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell (2008) 6.88
The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest (2006) 2.06
The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol (2006) 1.94
Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget (2010) 1.88
A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer (2011) 1.70
Stressin' Sestrins take an aging fight. EMBO Mol Med (2010) 1.65
Sestrins orchestrate cellular metabolism to attenuate aging. Cell Metab (2013) 1.58
Roles for the type III TGF-beta receptor in human cancer. Cell Signal (2010) 1.50
Deletion of XPC leads to lung tumors in mice and is associated with early events in human lung carcinogenesis. Proc Natl Acad Sci U S A (2005) 1.47
Retracted DNA methylation-associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers. Br J Cancer (2005) 1.45
Characterization of type III TGF-β receptor expression in invasive breast carcinomas: a potential new marker and target for triple negative breast cancer. J Cell Commun Signal (2014) 1.39
Lung cancer risk associated with selenium status is modified in smoking individuals by Sep15 polymorphism. Eur J Nutr (2008) 1.33
Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. Neoplasia (2008) 1.23
Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. BMC Cancer (2006) 1.20
Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer. J Clin Oncol (2010) 1.10
miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene (2012) 1.08
Role of CHD5 in human cancers: 10 years later. Cancer Res (2014) 0.99
The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer. Carcinogenesis (2010) 0.99
DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. PLoS Med (2009) 0.99
Sestrins at the crossroad between stress and aging. Aging (Albany NY) (2010) 0.98
Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications. Breast Cancer Res (2011) 0.95
The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells. Mol Biol Cell (2011) 0.95
Sestrin2 protein positively regulates AKT enzyme signaling and survival in human squamous cell carcinoma and melanoma cells. J Biol Chem (2014) 0.90
E2F2 suppresses Myc-induced proliferation and tumorigenesis. Mol Carcinog (2010) 0.87
Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study. Neuro Oncol (2007) 0.86
Epigenetic inactivation of the NORE1 gene correlates with malignant progression of colorectal tumors. BMC Cancer (2010) 0.85
Tumour suppressor HLJ1: A potential diagnostic, preventive and therapeutic target in non-small cell lung cancer. World J Clin Oncol (2014) 0.85
SPOC1-mediated antiviral host cell response is antagonized early in human adenovirus type 5 infection. PLoS Pathog (2013) 0.83
DEAR1 is a chromosome 1p35 tumor suppressor and master regulator of TGF-β-driven epithelial-mesenchymal transition. Cancer Discov (2013) 0.83
An ShRNA Based Genetic Screen Identified Sesn2 as a Potential Tumor Suppressor in Lung Cancer via Suppression of Akt-mTOR-p70S6K Signaling. PLoS One (2015) 0.82
Detailed genome-wide SNP analysis of major salivary carcinomas localizes subtype-specific chromosome sites and oncogenes of potential clinical significance. Am J Pathol (2013) 0.80
Update on the cytogenetics and molecular genetics of chordoma. Hered Cancer Clin Pract (2005) 0.80
CDK11p58 inhibits ERα-positive breast cancer invasion by targeting integrin β3 via the repression of ERα signaling. BMC Cancer (2014) 0.79
DEAR1, a novel tumor suppressor that regulates cell polarity and epithelial plasticity. Cancer Res (2014) 0.78
Decreased expression of the Id3 gene at 1p36.1 in ovarian adenocarcinomas. Br J Cancer (2001) 0.78
Identification of multiple DNA copy number alterations including frequent 8p11.22 amplification in conjunctival squamous cell carcinoma. Invest Ophthalmol Vis Sci (2014) 0.77
Downregulation of the tumor suppressor HSPB7, involved in the p53 pathway, in renal cell carcinoma by hypermethylation. Int J Oncol (2014) 0.77
Molecular and cellular pathways associated with chromosome 1p deletions during colon carcinogenesis. Clin Exp Gastroenterol (2011) 0.77
Loss of fragile histidine triad and amplification of 1p36.22 and 11p15.5 in primary gastric adenocarcinomas. World J Gastroenterol (2012) 0.77
Elevated C1orf63 expression is correlated with CDK10 and predicts better outcome for advanced breast cancers: a retrospective study. BMC Cancer (2015) 0.77
Novel p53 target gene FUCA1 encodes a fucosidase and regulates growth and survival of cancer cells. Cancer Sci (2016) 0.76
Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer. J Pathol (2014) 0.76
Estimating genomic instability mediated by Alu retroelements in breast cancer. Genet Mol Biol (2009) 0.75
Clinical significance of migration and invasion inhibitor protein expression in non-small-cell lung cancer. Oncol Lett (2014) 0.75
A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res (1988) 77.80
Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep (1966) 48.83
Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell (1997) 7.27
KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet (1997) 4.46
The retinoblastoma protein binds to a family of E2F transcription factors. Mol Cell Biol (1993) 3.75
Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet (1992) 3.13
Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med (1996) 2.66
Deletion of genes on chromosome 1 in endocrine neoplasia. Nature (1987) 2.27
A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem (1997) 2.00
A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc Natl Acad Sci U S A (1995) 1.82
TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95). Immunity (1997) 1.74
Deletions at chromosome 1p by fluorescence in situ hybridization are an early event in human colorectal tumorigenesis. Gastroenterology (1996) 1.66
Evidence for two tumour suppressor loci on chromosomal bands 1p35-36 involved in neuroblastoma: one probably imprinted, another associated with N-myc amplification. Hum Mol Genet (1995) 1.45
Alterations in the PITSLRE protein kinase gene complex on chromosome 1p36 in childhood neuroblastoma. Nat Genet (1994) 1.33
Tumour-suppressor genes: evolving definitions in the genomic age. Nat Genet (1997) 1.33
Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res (1993) 1.33
Deletion of 1p36 as a primary chromosomal aberration in intestinal tumorigenesis. Cancer Res (1993) 1.32
Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression. Proc Natl Acad Sci U S A (1989) 1.21
Heterogeneity for allelic loss in human breast cancer. J Natl Cancer Inst (1992) 1.14
ECK, a human EPH-related gene, maps to 1p36.1, a common region of alteration in human cancers. Genomics (1997) 1.10
Suppression of tumourigenicity in human colon carcinoma cells by introduction of normal chromosome 1p36 region. Oncogene (1993) 1.10
Accumulation of genetic changes during development and progression of hepatocellular carcinoma: loss of heterozygosity of chromosome arm 1p occurs at an early stage of hepatocarcinogenesis. Genes Chromosomes Cancer (1995) 1.07
Frequent genetic alterations at the distal region of chromosome 1p in human hepatocellular carcinomas. Cancer Res (1994) 1.06
Comparative genomic hybridization analysis of Wilms tumors. Cytogenet Cell Genet (1997) 1.05
Allelic loss at 1p is associated with tumor progression of meningiomas. Genes Chromosomes Cancer (1994) 1.04
Prognostic value of chromosome 1p allelic loss in colon cancer. Gastroenterology (1997) 1.02
Loss of heterozygosity identifies multiple sites of allelic deletions on chromosome 1 in human male germ cell tumors. Cancer Res (1994) 1.00
Frequent alterations of chromosome 1 in ductal carcinoma in situ of the breast. Oncogene (1995) 0.99
Detection of numerical and structural chromosome abnormalities in pediatric germ cell tumors by means of interphase cytogenetics. Genes Chromosomes Cancer (1994) 0.98
Characterization of the human homologue of RAD54: a gene located on chromosome 1p32 at a region of high loss of heterozygosity in breast tumors. Cancer Res (1997) 0.97
Physical mapping of the retinoblastoma interacting zinc finger gene RIZ to D1S228 on chromosome 1p36. Genomics (1996) 0.96
Assignment of human transforming growth factor-beta type I and type III receptor genes (TGFBR1 and TGFBR3) to 9q33-q34 and 1p32-p33, respectively. Genomics (1995) 0.95
Deletion mapping on chromosome 1p in well-differentiated gastric cancer. Br J Cancer (1996) 0.93
Loss of heterozygosity on the short arm of chromosomes 1 and 3 in sporadic pheochromocytoma and extra-adrenal paraganglioma. Hum Pathol (1997) 0.91
A p18 mutant defective in CDK6 binding in human breast cancer cells. Cancer Res (1996) 0.88
A tumor suppressor gene on chromosome 1p32-pter controls the amplification of MYC family genes in breast cancer. Cancer Res (1994) 0.87
The gene for the type II (p75) tumor necrosis factor receptor (TNF-RII) is localized on band 1p36.2-p36.3. Hum Genet (1991) 0.86
Reassignment of MYCL1 to human chromosome 1p34.3 by fluorescence in situ hybridization. Cytogenet Cell Genet (1996) 0.83
Human homologue of a candidate for the Mom1 locus, the secretory type II phospholipase A2 (PLA2S-II), maps to 1p35-36.1/D1S199. Cancer Res (1995) 0.82
Regional mapping of the human platelet-activating factor receptor gene (PTAFR) to 1p35-->p34.3 by fluorescence in situ hybridization. Cytogenet Cell Genet (1996) 0.82
Identification of the human ERK gene as a putative receptor tyrosine kinase and its chromosomal localization to 1p36.1: a comparative mapping of human, mouse, and rat chromosomes. Genomics (1995) 0.82
Frequent deletion of chromosome 1p sequences in an aggressive histologic subtype of endometrial cancer. Hum Mol Genet (1996) 0.81
Chromosomal localization of the human prostanoid receptor gene family. Genomics (1995) 0.81
The genomic organization and the full coding region of the human PAX7 gene. Genomics (1997) 0.79
Confirmed assignment of a novel human tyrosine kinase gene (JAK1A) to 1p32.3-->p31.3 by nonisotopic in situ hybridization. Cytogenet Cell Genet (1995) 0.79
Subregional mapping of the human lymphocyte-specific protein tyrosine kinase gene (LCK) to 1p35-->p34.3 and its position relative to the 1p marker D1S57. Cytogenet Cell Genet (1994) 0.79
Mapping of the 70 kDa, 34 kDa, and 11 kDa subunit genes of the human multimeric single-stranded DNA binding protein (hSSB/RPA) to chromosome bands 17p13, 1p35-p36.1, and 7p21-p22. Cell Struct Funct (1993) 0.78
Assignment of IL12RB1 and IL12RB2, interleukin-12 receptor beta 1 and beta 2 chains, to human chromosome 19 band p13.1 and chromosome 1 band p31.2, respectively, by in situ hybridization. Cytogenet Cell Genet (1997) 0.78
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet (1996) 4.38
Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation (2005) 2.77
High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res (1996) 2.43
Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. BMJ (1992) 2.39
Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet (1997) 2.28
Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. Cancer Res (1995) 2.14
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res (1997) 2.03
Cerebral microbleeds in the population based AGES-Reykjavik study: prevalence and location. J Neurol Neurosurg Psychiatry (2008) 1.99
Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet (1994) 1.88
Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer (1997) 1.82
Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc Natl Acad Sci U S A (1988) 1.76
Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype. Am J Hum Genet (1996) 1.75
Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci U S A (2000) 1.66
Linkage analysis of chromosome 17q markers and breast-ovarian cancer in Icelandic families, and possible relationship to prostatic cancer. Am J Hum Genet (1993) 1.38
Hand osteoarthritis in older women is associated with carotid and coronary atherosclerosis: the AGES Reykjavik study. Ann Rheum Dis (2008) 1.33
Cerebral microbleeds, retinopathy, and dementia: the AGES-Reykjavik Study. Neurology (2010) 1.29
The accuracy of death certificates. Implications for health statistics. Virchows Arch A Pathol Anat Histopathol (1991) 1.28
Mapping loss of heterozygosity at chromosome 13q: loss at 13q12-q13 is associated with breast tumour progression and poor prognosis. Eur J Cancer (1998) 1.28
The effect of a single BRCA2 mutation on cancer in Iceland. J Med Genet (2002) 1.26
Male-female differences in the association between incident hip fracture and proximal femoral strength: a finite element analysis study. Bone (2011) 1.24
Linkage to BRCA2 region in hereditary male breast cancer. Lancet (1995) 1.21
BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability. Cancer Res (1998) 1.20
Altered expression of E-cadherin in breast cancer. patterns, mechanisms and clinical significance. Eur J Cancer (2000) 1.14
Chromosome 17q-linkage seems to be infrequent in Icelandic families at risk of breast cancer. Acta Oncol (1995) 1.05
Identification of a novel splice-site mutation of the BRCA1 gene in two breast cancer families: screening reveals low frequency in Icelandic breast cancer patients. Hum Mutat (1998) 1.05
Loss of heterozygosity at chromosome 11 in breast cancer: association of prognostic factors with genetic alterations. Br J Cancer (1995) 1.04
Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma. Br J Cancer (2005) 1.04
Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer. Br J Cancer (1999) 1.04
High frequency of LOH, MSI and abnormal expression of FHIT in gastric cancer. Eur J Cancer (2002) 1.00
Primary cytomegalovirus infection and gastric ulcers in normal host. Dig Dis Sci (1991) 0.99
Gastric cancer after gastrectomy. Int J Cancer (1988) 0.98
Second primary malignancies in patients with male breast cancer. Br J Cancer (2005) 0.96
Age-related loss of proximal femoral strength in elderly men and women: the Age Gene/Environment Susceptibility Study--Reykjavik. Bone (2011) 0.95
High frequency of allelic imbalance at chromosome region 16q22-23 in human breast cancer: correlation with high PgR and low S phase. Int J Cancer (1995) 0.95
Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families. Eur J Hum Genet (2001) 0.95
pT4 stage II and III colon cancers carry the worst prognosis in a nationwide survival analysis. Shepherd's local peritoneal involvement revisited. Int J Cancer (2014) 0.94
Alterations of E-cadherin and beta-catenin in gastric cancer. BMC Cancer (2001) 0.94
Loss of heterozygosity at chromosome 7q in human breast cancer: association with clinical variables. Anticancer Res (1997) 0.94
The effect of mismatch repair deficiency on tumourigenesis; microsatellite instability affecting genes containing short repeated sequences. Int J Oncol (2000) 0.94
Replication error in colorectal carcinoma: association with loss of heterozygosity at mismatch repair loci and clinicopathological variables. Anticancer Res (1999) 0.93
Retinopathy in old persons with and without diabetes mellitus: the Age, Gene/Environment Susceptibility--Reykjavik Study (AGES-R). Diabetologia (2011) 0.93
Effects of age and sex on the strength and cortical thickness of the femoral neck. Bone (2010) 0.93
Effect of finite element model loading condition on fracture risk assessment in men and women: the AGES-Reykjavik study. Bone (2013) 0.92
Immature B cells in bone marrow express Fas/FasL. Scand J Immunol (2000) 0.92
Mitochondria, cell surface, and carcinogenesis. Int Rev Cytol Suppl (1983) 0.92
Papillary thyroid carcinoma in Iceland. A study of the occurrence in families and the coexistence of other primary tumours. Acta Oncol (1989) 0.92
Multiple chromosomal rearrangements in a spontaneously arising t(6;7) rat immunocytoma juxtapose c-myc and immunoglobulin heavy chain sequences. Proc Natl Acad Sci U S A (1986) 0.91
Polymorphism of the c-Ha-ras-1 proto-oncogene in sporadic and familial breast cancer. Int J Cancer (1989) 0.91
Inherited BRCA2 mutation associated with high grade breast cancer. Breast Cancer Res Treat (1998) 0.90
Associations of current and remitted major depressive disorder with brain atrophy: the AGES-Reykjavik Study. Psychol Med (2012) 0.90
Drosophila homolog of the murine Int-1 protooncogene. Proc Natl Acad Sci U S A (1988) 0.89
A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland. J Med Genet (1998) 0.88
Gene localization on sorted chromosomes: definitive evidence on the relative positioning of genes participating in the mouse plasmacytoma-associated typical translocation. Proc Natl Acad Sci U S A (1985) 0.87
Toxic and mutagenic effects of carcinogens on the mitochondria of Saccharomyces cerevisiae. Mol Gen Genet (1979) 0.87
p53 abnormality and chromosomal instability in the same breast tumor cells. Cancer Genet Cytogenet (2000) 0.87
Tubal metaplasia: a cytologic study with comparison to other neoplastic and non-neoplastic conditions of the endocervix. Diagn Cytopathol (1993) 0.86
Amplification of c-myc and pvt-1 homologous sequences in acute nonlymphatic leukemia. Leuk Res (1988) 0.86
TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. Br J Cancer (1996) 0.86
Risks of second primary cancer among patients with major histological types of lung cancers in both men and women. Br J Cancer (2010) 0.85
CYP17 promoter polymorphism and breast cancer risk in males and females in relation to BRCA2 status. Br J Cancer (2003) 0.85
Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis. APMIS (1997) 0.85
Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987. Scand J Urol Nephrol (2006) 0.84
Nucleotide sequence of the rat Bmyc gene. Oncogene (1989) 0.84
Identification of a breast tumor with microsatellite instability in a potential carrier of the hereditary non-polyposis colon cancer trait. Clin Genet (1995) 0.84
Brushing cytology of the upper gastrointestinal tract. Obsolete or not? Acta Cytol (1991) 0.84
Loss of heterozygosity on chromosome 9 in human breast cancer: association with clinical variables and genetic changes at other chromosome regions. Int J Cancer (1995) 0.83
Human interdigitating dendritic cells induce isotype switching and IL-13-dependent IgM production in CD40-activated naive B cells. J Immunol (2000) 0.83
Alterations of the FHIT gene in breast cancer: association with tumor progression and patient survival. Cancer Detect Prev (2001) 0.83
Loss of heterozygosity on chromosome arm 3p in nasopharyngeal carcinoma. Genes Chromosomes Cancer (1996) 0.82